Company: ZVRA
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001437749-25-016523
Chunk: 2

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 8
Chunk 2
---
 agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and William Blair & Company, L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”), in connection with the offering, issuance and sale by the Company of 
      9,230,770 shares of the Company’s common stock at a public offering price of
      $6.50 per share, pursuant to the 
       June 2024 Registration Statement and a related prospectus supplement dated 
       August 8, 2024, filed with the SEC (the 
       “August 2024 Offering”). Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option exercisable for 
      30 days to purchase up to an additional 
      1,384,615 shares of its Common Stock at the public offering price, less underwriting discounts and commissions, which the Underwriters exercised in full on 
       August 9, 2024. The 
       August 2024 Offering closed on 
       August 12, 2024. Total shares issued were 
      10,615,385. Net proceeds from the offering were approximately 
      $64.5 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds of the offering to support the commercialization of its approved products and the continued development of its product candidates, and for other general corporate purposes.

      Entry into 
      2024 
      ATM Agreement

       On 
       July 12, 2024, the Company entered into an equity distribution agreement (the 
      “2024 ATM Agreement”) with Citizens JMP Securities LLC (“Citizens JMP”) under which the Company 
       may offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to
      $75.0 million through Citizens JMP as its sales agent. The issuance and sale, if any, of common stock by the Company under the 
      2024 ATM Agreement will be made pursuant to the 
       June 2024 Registration Statement, the accompanying prospectus, and the related prospectus supplement dated 
       July 12, 2024. Citizens JMP 
       may sell the common stock by any method permitted by law deemed to be